Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Total Non-Current Liabilities (2019 - 2022)

SELLAS Life Sciences (SLS) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $16.1 million as the latest value for Q4 2022.

  • On a quarterly basis, Total Non-Current Liabilities rose 185.72% to $16.1 million in Q4 2022 year-over-year; TTM through Dec 2022 was $16.1 million, a 185.72% increase, with the full-year FY2022 number at $16.1 million, up 185.72% from a year prior.
  • Total Non-Current Liabilities was $16.1 million for Q4 2022 at SELLAS Life Sciences, up from $13.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $17.1 million in Q1 2022 to a low of -$19.2 million in Q2 2022.
  • A 4-year average of $6.5 million and a median of $5.9 million in 2019 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 185.72% in 2022; the steepest drop was 462.09% in 2022.
  • SELLAS Life Sciences' Total Non-Current Liabilities stood at $5.6 million in 2019, then skyrocketed by 140.1% to $13.5 million in 2020, then plummeted by 58.14% to $5.6 million in 2021, then skyrocketed by 185.72% to $16.1 million in 2022.
  • Per Business Quant, the three most recent readings for SLS's Total Non-Current Liabilities are $16.1 million (Q4 2022), $13.2 million (Q3 2022), and -$19.2 million (Q2 2022).